Date Filed | Type | Description |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/14/2023 |
8-K
| Quarterly results |
08/08/2023 |
8-K
| Investor presentation |
08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/25/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
07/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
06/08/2023 |
4
| MCDADE MARK (Director) has filed a Form 4 on Icosavax, Inc.
Txns:
| Granted 17,000 options to buy
@ $9.89, valued at
$168.1k
|
|
06/08/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Icosavax, Inc.
Txns:
| Granted 17,000 options to buy
@ $9.89, valued at
$168.1k
|
|
06/08/2023 |
4
| Wassil Jim (Director) has filed a Form 4 on Icosavax, Inc.
Txns:
| Granted 17,000 options to buy
@ $9.89, valued at
$168.1k
|
|
06/08/2023 |
4
| Veneman Ann M (Director) has filed a Form 4 on Icosavax, Inc.
Txns:
| Granted 17,000 options to buy
@ $9.89, valued at
$168.1k
|
|
06/08/2023 |
4
| Shiver John W. (Director) has filed a Form 4 on Icosavax, Inc.
Txns:
| Granted 17,000 options to buy
@ $9.89, valued at
$168.1k
|
|
06/08/2023 |
4
| FIELDS HEIDI (Director) has filed a Form 4 on Icosavax, Inc.
Txns:
| Granted 17,000 options to buy
@ $9.89, valued at
$168.1k
|
|
05/30/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 12.5% stake in Icosavax, Inc. |
05/25/2023 |
4
| Cearley Cassia (Chief Business Officer) has filed a Form 4 on Icosavax, Inc.
Txns:
| Sold 10,000 shares
@ $10, valued at
$100k
|
|
05/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
05/23/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/10/2023 |
8-K
| Quarterly results |
04/19/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/19/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/19/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/05/2023 |
4
| Holtzman Douglas (Chief Scientific Officer) has filed a Form 4 on Icosavax, Inc.
Txns:
| Sold 20,143 shares
@ $6.0785, valued at
$122.4k
Sold 300 shares
@ $6.56, valued at
$2k
Exercised 20,443 options to buy
@ $1.04, valued at
$21.3k
|
|
03/08/2023 |
4
| Cearley Cassia (Chief Business Officer) has filed a Form 4 on Icosavax, Inc.
Txns:
| Sold 5,000 shares
@ $7.7474, valued at
$38.7k
|
|
02/14/2023 |
5
| Russo Thomas Joseph (CFO) has filed a Form 5 on Icosavax, Inc. |
02/14/2023 |
5
| Kanesa-thasan Niranjan (Chief Medical Officer) has filed a Form 5 on Icosavax, Inc. |
|